Investor presentation
Investor presentation · Prasol Chemicals Limited has informed the Exchange about Investor Presentation
Source: Nse
Prasol Chemicals Limited (PRASOLCHEM)
Micro CapChemicals stocks · Micro cap · NSE
Prasol Chemicals Limited is a prominent manufacturer of acetone and phosphorous specialty derivatives with over three decades of legacy, 150+ specialty chemical products, and two manufacturing units in Khopoli and Mahad, serving 1,600+ customers globally across 65+ countries.
₹772.45
+17.80 · +2.36%
Market cap ₹4,765 Cr
Data qualityVerify one data layerQuote updated 04 Nov, 03:31 pm ISTPost-result recalculation pendingDetails
Quote04 Nov, 03:31 pm IST
Base fundamentals02 Nov 2026 · screener
Latest result02 Nov, 08:36 pm IST
Score05 Nov, 04:30 am IST · v4.3-runtime-valuation
Tags20 Sept 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Chemicals P/E 26.5 (n=46)
Technical timing lens
Trend score and candlestick chart
45NeutralMACD + · sector -4.4pp vs Nifty 500 (3M)
Stock trend: 56
Sector RS: 29
Sector 3M: -8.4% vs Nifty 500 -4.1%
Chemicals FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
PRASOLCHEMD candles · FIT view+15.1%Latest close ₹772.45 on 2026-11-04
Daily history is available from 2026-09-16; the requested 1Y window is partially covered.
Bar
+2.4%
RSI
54
MACD hist
7.34
52W pos
52%
2026-11-04O ₹754.00H ₹790.00L ₹745.60C ₹772.45Vol 75,917 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PRASOLCHEMNifty ChemicalsNifty 500
- PRASOLCHEM
- +15.1%
- Nifty 500
- +1.1%
- Nifty Chemicals
- -3.2%
- Vs Nifty 500
- +14.1 pp
Chart stats
4 Nov 2026- From 52W high
- -17.2%
- 52W range position
- 52%
- ATR (14)
- 6.8%
- Volume vs 20D
- 0.31x
- Avg traded value
- ₹18.3 Cr
- 20D price channel
- ₹676.1 - ₹933.1
₹933.1
₹601 - ₹933.1
₹52.5
Latest completed session
20-session average
65.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management trust is not scored yet, price trend is neutral, and result consistency is still building.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · OVERVALUED24
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Neutral45
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1936.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
pending—
Management reliability not computed yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Sept 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 02 Nov 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹412.6 Cr | NDF | -4.9% |
| EBITDA | ₹57.8 Cr | NDF | -35.8% |
| Operating margin | 14.0% | NDF | -700 bps |
| PAT | ₹38 Cr | NDF | -37.7% |
| PAT margin | 9.2% | NDF | -485 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 109.00
- P/B
- —
- EV/EBITDA
- 43.85
- Market Cap
- 4765.00Cr
Profitability
- ROE
- 12.60%
- ROCE
- 15.40%
- ROA
- 6.09%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 4.32%
- EPS 5Y
- -5.24%
- Revenue 3Y
- 12.00%
- EPS 3Y
- 12.00%
Balance Sheet
- Debt/Equity
- 0.28
- Interest Coverage
- 11.00×
- Altman Z
- 8.67
- Book Value
- —
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 22.00 Cr
- EPS TTM
- 7.51
Shareholding
- Promoter Hold
- 75.25%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 62%
Financial History
Updated 4/11/2026
Revenue
₹ CrLatest: 413-4.9% vs prev
Net Profit
₹ CrLatest: 38.0-37.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 54.
- RSI(14) at 54 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 17% off 52W high · 29% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
-
RS percentile
Insufficient history
1M return
-6.0%
3M return
-
6M return
-
1Y return
-
RS 1D
-
RS 20D
-
Sector rank
#15
Industry rank
-
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
unavailable
200-DMA
unavailable
Sector
lagging
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
34 observations
04 Nov 2026Value 113.92+1.24%
RS vs Nifty 500114
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth3/25
Quality5/20
Balance Sheet10/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
24
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
24/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 10/15 to the score.
- Quality contributes 5/20 to the score.
Main drags
- Fair-value margin of safety is negative at -1936.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
109.0
PB
—
EV/EBITDA
43.9
ROE
12.6%
ROCE
15.4%
FCF Yield
—
Debt/Equity
0.3
MoS
-1936.8%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 05 Nov 2026
v4.3-runtime-valuation
Final score
24
Previous: 24
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1936.8%
Previous: -1936.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
05 Nov 2026
v4.3-runtime-valuation
24
24
24
24
24
24
24
24
24
24
24
24
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
5.0
Growth-justified Value
₹37.93
-1936.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
JYOTIRES
Micro
Jyoti Resins & Adhesives Limited
Chemicals & Petrochemicals
match 172
26
25148.0
0.1%
-73363%
OVERVALUED
STEAMHOUSE
Micro
Steamhouse India Limited
Chemicals & Petrochemicals
match 144
40
84.0
25.3%
-97%
WATCHLIST
BALAMINES
Micro
Balaji Amines Limited
Specialty Chemicals
match 120
24
24.3
8.7%
-425%
OVERVALUED
CLEAN
Large
Clean Science and Technology Limited
Specialty Chemicals
match 113
41
32.6
15.3%
-206%
WATCHLIST
ALKYLAMINE
Micro
Alkyl Amines Chemicals Limited
Specialty Chemicals
match 111
68
34.3
41.4%
+17%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-10-29T00:40:13.726Z
Management commentary snapshot
Q1 FY27 revenue grew 36% YoY to Rs 433.6 crores, driven by higher realizations, volumes, and improved product mix, with EBITDA surging 122% YoY to Rs 90.3 crores aided by temporary geopolitical supply chain price increases.
The investment thesis remains intact as the company delivered its highest-ever quarterly performance, successfully turned around the Mahad facility to profitability, and maintained robust demand across acetone and phosphorus portfolios. However, analysts must look past the temporary Rs 25 crore gross profit tailwind from geopolitical supply chain disruptions.
Current business mix
Revenue Mix by Product
Latest issuer-disclosed distribution across 3 reported categories.
Acetone Based43.0%
Phosphorous Based38.0%
Others19.0%
Growth engines
Secondary and Tertiary Derivatives
ActiveGrowing contribution of high-margin secondary and tertiary derivatives in both acetone and phosphorus value chains.
New Product Pipeline
ActiveDeveloping more than 40 new products in the R&D pipeline at various stages with commercialization expected in coming years.
Mahad Facility Turnaround
ActiveTurnaround of the Mahad facility to a profitable trajectory with best-ever quarterly production.
Capacity and execution
Phase I Capacity Expansion
On SchedulePlanning Phase I expansion to add 60,000 MTPA to existing 98,844 MTPA capacity, reaching 1,58,844 MTPA by FY29 via debottlenecking and process augmentation.
Tailwinds
China Plus One and European Structural Crisis
PositiveLarge low-cost engineering talent pool in India, reduction in Chinese export subsidies, and European energy costs up 300% driving chemical offshoring to India.
Rising Domestic Consumption
PositiveIncreasing disposable income, consumer spending, rapid urbanization, and infrastructure development supporting domestic demand.
Headwinds
Geopolitical Supply Chain Disruptions
NegativeWest Asia conflict and geopolitical tensions held back export shipments and caused temporary supply chain friction.
Risk radar
Realization Normalization Risk
WatchManagement expects normalization of the temporary Rs 25 crores average selling price increase gained from geopolitical supply chain issues.
Long Customer Approval Cycles
PersistentTargeted specialty chemical markets require multi-year quality approval cycles (1-4 years), limiting rapid client acquisition.
Export Shipment Vulnerability
ActiveGlobal conflicts and regional tensions can restrict international logistics and shipment flows across the 65+ export countries.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
Both YoY and QoQ comparisons are relevant because YoY measures structural growth, scale expansion, and the recovery from past headwinds, while QoQ captures sequential demand momentum, utilization ramp-ups at Mahad, and pricing volatility.
Sector KPIs management disclosed
Total Revenue
PositiveTotal revenue was Rs 433.6 crores in Q1 FY27, representing a growth of 36% on a YoY basis.
EBITDA Margin
PositiveEBITDA margin reached 20.8% in Q1 FY27 compared to 12.7% in Q1 FY26, boosted by a temporary Rs 25 crores increase in average selling prices.
Capacity Utilization
PositiveMahad facility achieved its best-ever quarterly production with improved capacity utilization, building on FY26 utilization of 70-72%.
Exports vs Domestic
NeutralDomestic sales grew strongly, while exports grew YoY despite West Asia conflict-related geopolitical tensions holding back certain shipments.
Management forward view
FY27 Guidance
GuidedManagement expects FY27 revenue of Rs 1,550-1,650 crores and EBITDA of Rs 240-250 crores, excluding price fluctuations from geopolitical supply chain issues and forex impacts.
Long-Term Revenue Ambition
GuidedManagement aspires to achieve Rs 2,800-3,000 crores revenue over the next 5 years backed by Phase I and Phase II capex plans.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin Normalization | 20.8% in Q1 FY27 | Margin trajectory once the temporary Rs 25 crores ASP surge normalizes. |
| Phase I Capex Execution | Scheduled over next 2 years | Progress on Rs 250-300 crores investment and realization of peak revenue potential of Rs 500-550 crores. |
| Mahad Facility Profitability | Turned around in Q1 FY27 | Sustained positive operational contribution and steady capacity utilization ramp-up. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
Trust profile pending
Trust asks a simple question: can investors rely on management behaviour and financial delivery? Trust Lite uses promoter alignment, cash conversion, leverage, and result consistency. Full transcript-based claim matching appears after enough documents are ingested.
Continue researching Prasol Chemicals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationOct 2026
Oct 2026 · PPT
Source: Bse
Concall transcriptOct 2026
Oct 2026 · Transcript
Source: Bse
Concall transcriptJun 2026
Jun 2026 · Earnings-call transcript · Prasol Chemicals Limited has informed the Exchange about Transcript
Source: Nse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 29 Oct - Intimation of Schedule of Q2 FY27 Earnings Conference Call
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Sep - Q1 FY27 earnings conference call scheduled for 29 September 2026 at 11 a.m. IST.
Source: Bse
Investor presentation
Investor presentation · Prasol Chemicals Limited has informed the Exchange about Investor Presentation
Source: Nse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Sep - Newspaper Advertisement of Unaudited Standalone Financial Results for the Quater ended June 30, 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.